StocksMedium•28 September 2026•
1 min read
Mirum Pharmaceuticals Shares Fall Despite Positive Phase 3 Hepatitis D Data
Key Facts
1Mirum Pharmaceuticals' brelovitug met the primary endpoint in a Phase 3 study for chronic hepatitis D virus infection.
2The company's stock price declined despite the positive clinical trial results.
Mirum Pharmaceuticals announced that its drug brelovitug met the primary endpoint in a Phase 3 study for the treatment of chronic hepatitis delta virus infection. Seeking Alpha reported that the AZURE-1 study results showed positive outcomes for patients, marking a significant clinical milestone for the company.
The company's stock price declined during trading on September 28, 2026, despite the successful clinical trial results. This downward movement suggests that market expectations may have already been priced in or that investors are focusing on secondary data points and the commercial outlook for the treatment.